Hydrogen Peroxide Biocides: EU Authorization 2026 and What Manufacturers Must Do

Key data

Manufacturers and distributors of hydrogen peroxide-based biocides have had a new compliance obligation since 23 April 2026: to adapt all their technical documentation, labels and safety data sheets to the terms of the Implementing Regulation (EU) 2026/891. In return, they obtain the right to market these products in any Member State without processing individual national authorizations.

This Union authorization, granted under the Regulation (EU) No 528/2012 on biocides, is one of the most efficient routes of access to the European single market for this type of product. But the advantage comes with strict conditions.

What does this regulation establish?

Regulation 2026/891 grants Union authorization for the family of biocides called Hydrogen Peroxide Products, whose active substance is hydrogen peroxide. This centralized authorization has three main effects:

• Pan-European access without national authorizations: The authorization holder can market the products in all EU Member States without the need to process country-by-country permits.
• Obligation to comply with annex specifications: Products must strictly comply with the technical conditions and specifications established in the annex of the regulation.
• Mandatory documentary adaptation: Labels, safety data sheets and technical documentation must be adjusted to the terms of the authorization granted.

Hydrogen peroxide is one of the most widely used disinfectant substances in Europe, with applications in sectors as diverse as healthcare, the food industry and industrial production. The authorization of this family of products under a single European framework significantly simplifies the operations of those who manufacture or distribute them on a community scale.

Economic and operational impact

Centralized authorization eliminates the need to obtain national permits in each of the 27 Member States, which represents significant savings in time and administrative costs for companies with European distribution.

However, the counterpart is immediate: all documentation linked to these products must be reviewed and adapted. This includes:

• Review and update of product labels in accordance with the annex of Regulation 2026/891.
• Update of safety data sheets to reflect the conditions of the authorization.
• Review of technical documentation internal and submitted to competent authorities.

The economic risk from non-compliance is direct: the regulation establishes that failure to comply with the conditions may result in market withdrawal of the product or administrative sanctions. For companies with products already distributed, a withdrawal implies logistical costs, reputational damage and potential customer claims.

Who does it affect?

• Manufacturers of hydrogen peroxide-based biocides that market or intend to market in the EU.
• Distributors of the Hydrogen Peroxide Products family in one or more Member States.
• Professional users of these biocides in sectors such as healthcare, food and industry who must verify that the products they use have current authorization.
• Compliance and regulatory officers (Regulatory Affairs) in companies in the chemical and industrial hygiene sector.
• Advisors and consultants providing services to companies manufacturing or distributing biocides in Europe.

Practical example

A Spanish company manufacturing disinfectant solutions for the food sector that uses hydrogen peroxide as the active substance and distributes its products in Spain, France and Germany faces the following situation:

Until now, it could have been operating with national authorizations in each of those three countries. With the entry into force of Regulation 2026/891, it can benefit from the Union authorization for the Hydrogen Peroxide Products family, which allows it to operate under a single regulatory framework for the entire EU.

However, to benefit from this centralized authorization, it must immediately review its labels, safety data sheets and technical documentation to ensure they comply with the specifications in the annex of the regulation. If its current labels do not conform to the new terms and a market inspector detects the discrepancy, the product may be withdrawn from the market in any of the countries where it operates.

What should companies do now?

1. Verify whether their products are included in the Hydrogen Peroxide Products family authorized by Regulation 2026/891, by consulting the text and annex of the regulation in the Official Journal of the EU.
2. Review current labels of all affected products and compare them with the technical specifications in the annex of the regulation to identify discrepancies.
3. Update safety data sheets in accordance with the terms of the authorization granted, ensuring consistency with the new regulatory framework.
4. Review technical documentation internal and submitted to competent authorities to ensure its alignment with Regulation 2026/891.
5. Communicate changes to the distribution chain, informing distributors and professional customers of documentary and labeling updates.
6. Establish a monitoring process to detect any future changes to the conditions of the authorization that may require further adaptations.